单药卡铂AUC10治疗转移性精原细胞瘤:英国多中心216例研究
该多中心回顾性分析纳入216例国际生殖细胞癌协作组预后良好型转移性精原细胞瘤患者,接受卡铂AUC10每21天方案。3年无进展生存率96.5%,5年疾病特异性生存率98.3%,无治疗相关死亡;主要急性毒性为骨髓抑制,3级及以上中性粒细胞减少和血小板减少分别为37%和27%。
要点
- 卡铂AUC10在预后良好转移性精原细胞瘤中3年PFS达96.5%,5年DSS达98.3%。
- 主要急性毒性为骨髓抑制,3级及以上中性粒细胞减少37%、血小板减少27%。
- 卡铂AUC10可作为预后良好转移性精原细胞瘤的另一种标准治疗选择。
核心结论
- 卡铂AUC10治疗转移性精原细胞瘤的肿瘤学疗效与现有标准治疗相似,失败风险低。
研究设计与样本
- 多机构回顾性分析纳入截至2018年所有接受卡铂AUC10每21天方案的国际生殖细胞癌协作组预后良好型转移性精原细胞瘤男性患者,共216例。
主要发现
- 3年无进展生存率为96.5%,5年疾病特异性生存率为98.3%。
- 共7例复发,其中5例经进一步化疗±手术成功挽救,3例非精原细胞瘤相关死亡。
- 无治疗相关死亡。
- 148例可评估毒性患者中,37%和27%分别发生3级及以上中性粒细胞减少和血小板减少。
临床怎么用
- 卡铂AUC10可作为预后良好型转移性精原细胞瘤的另一种标准治疗选择,其毒性可能低于其他疗法。
局限性
- 为多机构回顾性分析,毒性数据仅148/216例可评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be a less toxic alternative; however early historic studies at AUC7 showed inferior outcomes. OBJECTIVES: To evaluate multi-institutional data on and toxicity and longer-term survival for metastatic seminoma patients treated with the single-agent carboplatin AUC10. METHODS: We undertook a multi-institutional analysis incorporating all men with the International Germ Cell Cancer Collaborative Group good-prognosis metastatic seminoma treated until 2018. Carboplatin AUC10 was given every 21 days. Toxicity, progression-free survival (PFS), disease-specific survival (DSS) and overall survival were noted. Variables predictive of progression were identified. RESULTS AND LIMITATIONS: 216 patients were treated. The three-year PFS rate was 96.5%, and five-year DSS was 98.3%. There were seven relapses, of which 5 were successfully salvaged with further chemotherapy ± surgery, and three non-seminoma-related deaths. There were no treatment-related deaths. Of 148/216 evaluable patients for toxicity, 37% and 27% suffered >/ = grade III neutropenia and thrombocytopenia, respectively. Twelve percent of patients needed a platelet or blood transfusion (or both). The incidence of febrile neutropenia was 5%. CONCLUSION: For metastatic seminoma, carboplatin AUC10 harbours a similar oncological efficacy to established therapies, with a low failure risk. The major acute toxicity was myelosuppression. Our study establishes carboplatin AUC10 as another standard-of-care treatment option for good-prognosis metastatic seminoma, with a potentially lower toxicity profile than other therapies.
引用
- Alifrangis C, Sharma A, Chowdhury S, et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. Eur J Cancer. 2020. PMID: 33041185. doi:10.1016/j.ejca.2020.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。